ClinicalTrials.gg
Status unknownNCT05602792Updated Nov 2, 2022

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of T3011 and T3011 in Advanced Solid Tumor, Sarcoma and HNSCC, sponsored by ImmVira Pharma Co. Ltd. Status unknown at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-02.

Primary conditionnone(registry's first term: Sarcoma)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Sarcoma, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by ImmVira Pharma Co. Ltd · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Apr 2020, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
233
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors

Read the detailed description

This is a Phase I/IIa, open-label, first-in-human study of T3011 given via intratumoral (IT) injection in participants with advanced or metastatic solid tumors. Part I and part II of the study is a dose escalation which will use a 3+3 design to evaluate escalating doses of T3011. Part I is a single dose escalation. Part II is multiple dose escalation. Total enrollment will depend on the toxicities and/or activity observed, with approximately 8-48 evaluable participants enrolled.

Once the RP2D is established ,Part III will enroll approximately 40-60 participants with sarcoma , approximately 10-25 participants with Malignant head and neck tumor,approximately 10-25 participants with breast cancer,approximately 10-25 participants with esophagus cancer,approximately 10-25 participants with lung cancer and approximately 10-25 participants with non-melanoma skin cancer.

02

Conditions studied

  • Advanced Solid Tumor
  • Sarcoma
  • HNSCC
  • Breast Cancer
  • Esophagus Cancer
  • NSCLC
  • Non-melanoma Skin Cancer

Keywords

  • Oncolytic virus
  • Herpes virus
03

In context

Lead sponsor

ImmVira Pharma Co. Ltd is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age 18\~70 years Part I ; Age 18 years or older (Part II and III ). 2. or pathologically confirmed diagnosis of locally recurrent or advanced .

      1. per version 1.1. 4. Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the opinion of the investigator.
      1. (ECOG) performance status 0-1. 6. > 12 weeks. 7. Women of (WCBP) and men must agree to use adequate prior to study entry, while on study treatment, and for six months after receiving last dose of T3011.
      1. WCBP must have a negative serum pregnancy test Within 7 days prior to W1D1. 9. Capable of understanding and complying with protocol requirements.

Exclusion criteria

Exclusion Criteria:

    1. Last dose of previous anticancer therapy \< 4 weeks. 2. Prior treatment with another oncolytic virus or gene therapy. 3. Previous intolerance to anti-PD-(L)1 monoclonal antibody or previous history of immunotherapy induced non-infectious pneumonitis/interstitial lung disease.

      1. History of seizure disorders within 12 months of Screening. 5.History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or monoclonal antibody.
      1. Requires continued concurrent therapy with any drug active against HSV. 7. Pregnant or lactating.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
233 participants (estimated)

Study arms

  • Experimental
    T3011 Herpes Virus Injection

    Biological: T3011

Interventions

06

What researchers measure

Primary outcomes

  1. In part I and part II, Evaluate the safety and tolerability of escalating doses of single dose and multiple dose IT T3011.Characterize DLTs and identify the MTD of IT T3011.

    Incidence rate of TEAE; Incidence rate of DLT

    Time frame: Up to 2 years from first dose of T3011

  2. In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.

    Incidence rate of TEAE;

    Time frame: Up to 2 years from first dose of T3011

Secondary outcomes

  1. In part I and part II, Characteristics of biological distribution and biological effect of single dose and multiple dose IT T3011.

    The changes of PD-1 and IL-12 concentration after administration

    Time frame: Up to 2 years from first dose of T3011

  2. In part I and part II, Evaluation of pharmacodynamics of T3011

    IFN-γ、 IL-1β、 IL-2、 IL-4、 IL-6、 IL-8、 IL-10、 IL-13、 TNF-α

    Time frame: Up to 2 years from first dose of T3011

  3. In part I and part II, Evaluation of immunogenicity of T3011

    ADAs and Nabs of IL-12, anti-PD-1 antibody and HSV-1

    Time frame: Up to 2 years from first dose of T3011

  4. Overall response rate (ORR)

    ORR is defined as the proportion of participants who have a partial response (PR) or complete response (CR) to intervention, based on assessments by RECIST v1.1 and iRECIST.

    Time frame: Up to 2 years from first dose of T3011

  5. Disease control rate (DCR)

    DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) based on assessments by RECIST v1.1 and iRECIST.

    Time frame: Up to 2 years from first dose of T3011

  6. Duration of response (DOR)

    DOR is defined as the time from the first met CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years from first dose of T3011

  7. Progression-free survival (PFS)

    PFS is defined as the time from enrollment to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RECIST v1.1 and iRECIST.

    Time frame: Up to 2 years from first dose of T3011

  8. In part III,Overall Survival (OS)

    OS is defined as the time from enrollment to death from any cause.

    Time frame: Up to 2 years from first dose of T3011

Other outcomes

  1. In part II and part III,Exploring tumor immunomodulatory mechanism and histological changes after IT T3011

    Assesse histological changes by immunohistochemical fluorescence detection

    Time frame: Up to 2 months from first dose of T3011

  2. In part II and part III,Exploring the relationship between genetic changes and drug efficacy

    Genetic testing of tumor tissue

    Time frame: Up to 2 months from first dose of T3011

  3. In part II and part III,Exploring the proliferation and activity of immune cells in blood after IT T3011

    Analysis of immune cells in blood

    Time frame: Up to 2 years from first dose of T3011

07

Study locations

18 of 19 sites recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
    Recruiting
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
    Recruiting
  • The Fifth Affiliated Hospital of Sun Yat-sen University
    Guanzhou, Guangdong 528406, China
    Recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
    Recruiting
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
    Recruiting
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 330029, China
    Recruiting
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110042, China
    Recruiting
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
    Recruiting
  • The First Affiliated Hospital of Zhejiang University Medical College
    Hanzhou, Zhejiang 310003, China
    Recruiting
  • Zhejiang Provincial People's Hospital
    Hanzhou, Zhejiang 314408, China
    Recruiting
  • Peking University First Hospital
    Beijing, 100034, China
    Recruiting
  • Beijing Jishuitan Hospital
    Beijing, 100035, China
    Recruiting
  • Ninth People's Hospital,Shanghai Jiao Tong University School to Medicine
    Shanghai, 200011, China
    Recruiting
  • Fudan University Cancer Hospital
    Shanghai, 200032, China
    Recruiting
  • Zhongshan Hospital
    Shanghai, 200032, China
    Recruiting
  • Shanghai Sixth People's Hospital
    Shanghai, 200233, China
    Not yet recruiting
  • The Second People's Hospital of Shenzhen
    Shenzhen, 518025, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2020 (actual). Primary completion is estimated for Jul 2023, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Nov 2, 2022
StartActual
Apr 21, 2020
Primary completionEst.
Jul 2023
CompletionEst.
Jan 2024
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05602792
Lead sponsor
ImmVira Pharma Co. Ltd
Responsible party
Sponsor
First posted
Nov 2, 2022
Start date
Apr 21, 2020
Primary completion
Jul 2023 (estimated)
Completion
Jan 2024 (estimated)
Last update
Nov 2, 2022

Study contacts

ImmVira Pharma Co. LTD
Contact
clinicaltrials@immviragroup.com
781-718-5121

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011

Start the discussion